Clinic
The Unity Hospital of Rochester
The Unity Hospital of Rochester was paid $55.30M by Medicaid between Jan 2018 and Dec 2024, across 290 billing codes. Its largest line is 99283, emergency room visit (moderate) — 9.5% of everything it billed.
33Billing provider infoTHE UNITY HOSPITAL OF ROCHESTER
ROCHESTER, NY 14626
ROCHESTER, NY 14626
33aNPI1760421713assigned 06/05/2006
33bProvider typeComprehensive Outpatient Rehabilitation Facility (CORF)
28Total paid$55.30M
24GClaims689,216
24DCodes billed290
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Comprehensive Outpatient Rehabilitation Facility (CORF) providers in New York
Rank by total paid#1 of 6
Median peer was paid$1.33M
This provider vs. median42×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,181 | $517K | |
| 2019 | 40,535 | $3.08M | |
| 2020 | 110,059 | $8.37M | |
| 2021 | 135,821 | $10.50M | |
| 2022 | 143,890 | $11.41M | |
| 2023 | 147,774 | $12.28M | |
| 2024incomplete | 103,956 | $9.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.5% | 43,889 | 42,571 | $5.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.3% | 26,499 | 25,200 | $5.12M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.7% | 33,555 | 28,565 | $4.28M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.6% | 25,670 | 24,691 | $3.64M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.2% | 16,166 | 14,203 | $3.42M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.9% | 32,161 | 28,459 | $3.28M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.7% | 17,143 | 15,077 | $1.47M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.4% | 1,766 | 1,764 | $1.31M |
| 59025 | Fetal non-stress test | 2.3% | 7,929 | 4,322 | $1.27M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 3,835 | 3,770 | $1.22M |
| 64483 | 2.1% | 1,933 | 1,888 | $1.18M | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.9% | 1,436 | 1,431 | $1.03M |
278 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 7,088 | $1.00M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 6,757 | $955K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.7% | 4,766 | $949K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 3,289 | $940K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 16,466 | $938K |
| 80053 | Comprehensive metabolic panel | 1.4% | 32,727 | $756K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 4,063 | $744K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 1,895 | $600K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 15,427 | $588K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,918 | $527K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,262 | $508K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,644 | $501K |
| 64615 | <1% | 1,335 | $471K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,436 | $443K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 9,823 | $433K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,858 | $422K |
| 97597 | <1% | 1,213 | $413K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,932 | $397K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,105 | $386K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 7,516 | $385K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,074 | $375K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 714 | $366K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12,919 | $362K |
| 87631 | <1% | 5,397 | $337K | |
| 97113 | <1% | 4,255 | $333K | |
| 97161 | <1% | 3,609 | $327K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15,471 | $321K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,662 | $321K |
| 93975 | <1% | 1,026 | $306K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,519 | $299K |
| 76801 | <1% | 5,022 | $295K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 358 | $254K |
| 76770 | <1% | 546 | $247K | |
| 97162 | <1% | 2,184 | $240K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 3,068 | $231K |
| 76830 | Ultrasound, transvaginal | <1% | 4,101 | $210K |
| 10060 | <1% | 653 | $191K | |
| 12001 | <1% | 536 | $182K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,094 | $176K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,462 | $171K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,435 | $165K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 254 | $155K |
| G0378 | Hospital observation service, per hour | <1% | 1,398 | $148K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,303 | $142K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 983 | $140K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,264 | $119K |
| 86850 | <1% | 3,800 | $113K | |
| 97116 | <1% | 2,604 | $107K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,522 | $106K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 233 | $105K |
| 58340 | <1% | 301 | $103K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,889 | $95K |
| 76813 | <1% | 2,530 | $91K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,806 | $91K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 919 | $89K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 122 | $88K |
| 93970 | <1% | 235 | $86K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,399 | $84K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 646 | $78K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,594 | $77K |
| 93971 | <1% | 811 | $77K | |
| 81025 | <1% | 19,861 | $74K | |
| 86901 | <1% | 3,792 | $72K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 115 | $72K |
| 94060 | <1% | 823 | $68K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 220 | $68K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,496 | $67K |
| 93798 | <1% | 2,212 | $67K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 558 | $67K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,617 | $66K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,978 | $64K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 544 | $63K |
| 90715 | <1% | 2,433 | $62K | |
| 93017 | <1% | 503 | $62K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 308 | $61K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,281 | $57K |
| 95886 | <1% | 697 | $57K | |
| 86900 | <1% | 3,829 | $57K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,070 | $51K |
| 93458 | <1% | 36 | $50K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 411 | $48K |
| 88342 | <1% | 871 | $46K | |
| 99385 | <1% | 352 | $44K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 481 | $42K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,243 | $42K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,015 | $40K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,428 | $39K |
| 91320 | <1% | 312 | $39K | |
| 93351 | <1% | 148 | $38K | |
| D0120 | Dental checkup, returning patient | <1% | 796 | $34K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,661 | $33K |
| 74740 | <1% | 209 | $33K | |
| 88307 | <1% | 327 | $32K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,126 | $31K |
| 90686 | <1% | 1,541 | $31K | |
| 88304 | <1% | 647 | $30K | |
| 84484 | <1% | 6,049 | $29K | |
| 83880 | <1% | 841 | $27K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,260 | $27K |
| 20553 | <1% | 108 | $23K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 76 | $23K |
| 0124A | <1% | 555 | $22K | |
| 95811 | <1% | 24 | $19K | |
| 94727 | <1% | 1,140 | $18K | |
| 80061 | Lipid panel | <1% | 1,140 | $17K |
| 90682 | <1% | 563 | $17K | |
| 87480 | <1% | 5,542 | $17K | |
| 87660 | <1% | 5,547 | $16K | |
| 87510 | <1% | 5,526 | $16K | |
| 94729 | <1% | 1,321 | $16K | |
| 0054A | <1% | 390 | $15K | |
| 90677 | <1% | 374 | $15K | |
| 92551 | <1% | 222 | $15K | |
| C8930 | Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision | <1% | 53 | $15K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 419 | $14K |
| 0001A | <1% | 397 | $14K | |
| 12011 | <1% | 42 | $14K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,303 | $14K |
| 84702 | <1% | 2,536 | $14K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 13 | $13K |
| 20610 | <1% | 47 | $11K | |
| 83690 | <1% | 4,361 | $11K | |
| 0071A | <1% | 264 | $11K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,131 | $11K |
| 90480 | <1% | 288 | $10K | |
| 0004A | <1% | 244 | $10K | |
| 0002A | <1% | 240 | $10K | |
| 29125 | <1% | 58 | $9K | |
| 73130 | <1% | 710 | $9K | |
| 87634 | <1% | 342 | $9K | |
| 85027 | <1% | 2,289 | $9K | |
| 94010 | <1% | 306 | $9K | |
| 73030 | <1% | 598 | $8K | |
| 73630 | <1% | 527 | $8K | |
| 0051A | <1% | 196 | $8K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,114 | $8K |
| 82803 | <1% | 246 | $7K | |
| 87081 | <1% | 2,431 | $7K | |
| 70496 | <1% | 25 | $7K | |
| 0052A | <1% | 169 | $7K | |
| 0072A | <1% | 160 | $7K | |
| 76825 | <1% | 93 | $7K | |
| 73564 | <1% | 180 | $7K | |
| 76820 | <1% | 393 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,788 | $7K |
| 58300 | <1% | 37 | $6K | |
| 80076 | <1% | 517 | $6K | |
| G0008 | Administration of influenza virus vaccine | <1% | 534 | $6K |
| 93356 | <1% | 43 | $6K | |
| 86780 | <1% | 2,067 | $6K | |
| 99493 | <1% | 88 | $6K | |
| 73562 | <1% | 552 | $6K | |
| 62323 | <1% | 13 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,034 | $6K |
| 62321 | <1% | 12 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,066 | $5K |
| 85610 | <1% | 1,214 | $5K | |
| 73610 | <1% | 486 | $5K | |
| 82947 | <1% | 846 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,811 | $4K |
| 81001 | <1% | 3,596 | $4K | |
| 87653 | <1% | 113 | $4K | |
| 70491 | <1% | 12 | $4K | |
| 72100 | <1% | 222 | $3K | |
| 87040 | <1% | 737 | $3K | |
| 83655 | <1% | 261 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 95 | $3K |
| 73140 | <1% | 119 | $3K | |
| 99442 | <1% | 258 | $3K | |
| 99173 | <1% | 578 | $3K | |
| 81002 | <1% | 3,583 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 118 | $3K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 76 | $3K |
| 83605 | <1% | 726 | $3K | |
| 83735 | <1% | 837 | $3K | |
| 87186 | <1% | 803 | $2K | |
| 71271 | <1% | 52 | $2K | |
| 87077 | <1% | 907 | $2K | |
| 95885 | <1% | 25 | $2K | |
| 76827 | <1% | 93 | $2K | |
| 90656 | <1% | 113 | $2K | |
| 90673 | <1% | 74 | $2K | |
| 73502 | <1% | 155 | $2K | |
| 81003 | <1% | 1,853 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 54 | $2K |
| 87070 | <1% | 1,113 | $2K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 34 | $2K |
| 82040 | <1% | 421 | $2K | |
| 36591 | <1% | 33 | $2K | |
| 85379 | <1% | 449 | $2K | |
| 85018 | <1% | 1,010 | $2K | |
| 80306 | <1% | 311 | $2K | |
| 90651 | <1% | 14 | $2K | |
| 73110 | <1% | 87 | $1K | |
| 99443 | <1% | 92 | $1K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,023 | $1K |
| 88341 | <1% | 26 | $1K | |
| 88142 | <1% | 41 | $1K | |
| 0081A | <1% | 30 | $1K | |
| 95909 | <1% | 13 | $1K | |
| 90670 | <1% | 190 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 20 | $1K |
| 99441 | <1% | 81 | $1K | |
| 82565 | <1% | 243 | $1K | |
| 96376 | <1% | 824 | $1K | |
| 93797 | <1% | 38 | $959.63 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 20 | $916.30 |
| 99406 | <1% | 28 | $902.24 | |
| 97165 | <1% | 15 | $875.94 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 26 | $848.53 |
| 90697 | <1% | 42 | $796.96 | |
| 87641 | <1% | 38 | $787.34 | |
| 80050 | General health panel | <1% | 28 | $722.96 |
| G0009 | Administration of pneumococcal vaccine | <1% | 70 | $701.58 |
| 86703 | <1% | 44 | $698.96 | |
| 87252 | <1% | 17 | $697.77 | |
| 90619 | <1% | 24 | $671.18 | |
| 0011A | <1% | 50 | $647.38 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 12 | $592.50 |
| 0012A | <1% | 33 | $563.92 | |
| 87430 | <1% | 74 | $502.86 | |
| 86803 | <1% | 295 | $489.19 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 176 | $482.21 |
| 74018 | <1% | 26 | $459.27 | |
| 84132 | <1% | 106 | $453.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 15 | $429.80 |
| 90633 | <1% | 15 | $376.50 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 14 | $356.20 |
| 90710 | <1% | 13 | $351.42 | |
| 84439 | <1% | 122 | $347.11 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,405 | $315.74 |
| 87147 | <1% | 105 | $292.72 | |
| 82570 | <1% | 417 | $287.49 | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 77 | $280.78 |
| 87088 | <1% | 112 | $273.49 | |
| 84703 | <1% | 85 | $245.19 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,202 | $241.68 |
| 87340 | <1% | 454 | $188.71 | |
| 86762 | <1% | 122 | $179.28 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 320 | $175.59 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,419 | $168.46 |
| 90662 | <1% | 40 | $134.89 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 581 | $113.42 |
| 84156 | <1% | 182 | $108.15 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 94 | $97.88 |
| 86580 | <1% | 16 | $91.89 | |
| 82728 | <1% | 12 | $71.82 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,986 | $64.35 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,205 | $62.58 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,662 | $61.39 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 562 | $40.58 |
| 83540 | <1% | 24 | $40.33 | |
| 84550 | <1% | 41 | $35.20 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 205 | $34.40 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,331 | $29.51 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 799 | $24.30 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 968 | $13.58 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 36 | $13.41 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 496 | $13.06 |
| 82607 | <1% | 12 | $7.88 | |
| 83550 | <1% | 12 | $5.38 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 125 | $4.31 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 426 | $2.39 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 20 | $2.10 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 13 | $1.96 |
| A4215 | Needle, sterile, any size, each | <1% | 12 | $1.68 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 407 | $0.63 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 13 | $0.17 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 60 | $0.03 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 32 | $0.01 |
| 86696 | 0% | 13 | $0.00 | |
| 90734 | 0% | 42 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 14 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 13 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 15 | $0.00 |
| 90698 | 0% | 13 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTEWART, DOUGLAS (PRESIDENT HEALTH CARE SERVICES)
| Provider | Location | Paid |
|---|---|---|
| The Unity Hospital of Rochester | Rochester, NY | $36.77M |
| The Unity Hospital of Rochester | Rochester, NY | $28.32M |
| The Unity Hospital of Rochester | Rochester, NY | $25.87M |
| The Unity Hospital of Rochester | Rochester, NY | $34K |
| The Unity Hospital of Rochester | Rochester, NY | $6K |
| Alex City Foot Specialties, LLC | Alexander City, AL | $740.95 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.